Reduction in the Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic TransplantationAmeet Patel, Adetola A. Kassim, Bipin N. Savani et al.|Transplantation and Cellular Therapy|2022Cited by 3
Effective Desensitization Strategy for Patients with Sickle Cell Disease with High Donor Specific Antibodies Undergoing Haploidentical Bone Marrow Transplant with Posttransplant CyclophosphamideEden Biltibo, Josu de la Fuente, J. Connelly et al.|Blood|2022Cited by 0
The Combination of Rituximab, Plasmapheresis, Intravenous Immunoglobulins and Pre-Transplant Immunosuppression Is an Effective Desensitization Strategy for Patients with Sickle Cell Disease and High Donor Specific Anti-Human Leukocyte Antigen Titer Undergoing Haploidentical Bone Marrow TransplantEden Biltibo, Josu de la Fuente, Reena Jayani et al.|Transplantation and Cellular Therapy|2023Cited by 0
ABO Incompatibility Did Not Impact Outcomes after Haploidentical Bone Marrow Transplantation with Posttransplant Cyclophosphamide for Patients with Sickle Cell Disease: Single Center ExperienceDanielle Murphy, Adetola A. Kassim, Karina Wilkerson et al.|Transplantation and Cellular Therapy|2023Cited by 0